N/A
Manufactured by Sumitomo Pharma America, Inc.
42,043 FDA adverse event reports analyzed
Last updated: 2026-05-19
Latuda is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Sumitomo Pharma America, Inc.. The most commonly reported adverse reactions for Latuda include OFF LABEL USE, DRUG INEFFECTIVE, ANXIETY, FEELING ABNORMAL, DEPRESSION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for Latuda.
Out of 20,651 classified reports for Latuda:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 42,043 FDA FAERS reports that mention Latuda. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include OFF LABEL USE, DRUG INEFFECTIVE, ANXIETY, FEELING ABNORMAL, DEPRESSION, WEIGHT INCREASED. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Sumitomo Pharma America, Inc. in connection with Latuda. Always verify the specific product and NDC with your pharmacist.
Explore other medications manufactured by Sumitomo Pharma America, Inc. and compare their safety profiles:
The following drugs share commonly reported adverse reactions with Latuda: